CKDXF (Opthea) Long-Term Debt: $0.00 Mil (As of Jun. 2025)


What is Opthea Long-Term Debt?

Opthea CKDXF Long-Term Debt is $0.00 Mil as of Jun. 2025. The stock has 3 warning signs investors should review.

Opthea's Long-Term Debt for the quarter that ended in Jun. 2025 was $0.00 Mil.

Opthea's quarterly Long-Term Debt increased from Jun. 2024 ($141.55 Mil) to Dec. 2024 ($157.21 Mil) but then declined from Dec. 2024 ($157.21 Mil) to Jun. 2025 ($0.00 Mil).

Opthea's annual Long-Term Debt increased from Jun. 2023 ($85.66 Mil) to Jun. 2024 ($141.55 Mil) but then declined from Jun. 2024 ($141.55 Mil) to Jun. 2025 ($0.00 Mil).

Opthea  (OTCPK:CKDXF) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Opthea Long-Term Debt Related Terms

Opthea Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Opthea's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Opthea Long-Term Debt Chart

Opthea Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 85.66 141.55 0.00

Opthea Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 85.66 0.00 141.55 157.21 0.00
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.00 Mil mean?
Opthea (CKDXF) has a Long-Term Debt of $0.00 Mil as of Jun. 2025.
Is Opthea's Long-Term Debt too high?
Opthea's current Long-Term Debt is $0.00 Mil.
How does Opthea's Long-Term Debt compare to VRTX and REGN?
Opthea's Long-Term Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Opthea's current Long-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Opthea stock overvalued right now?
Opthea (CKDXF) has a current Long-Term Debt of $0.00 Mil. The current Long-Term Debt is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Opthea (CKDXF), the current Long-Term Debt is $0.00 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Opthea Business Description

Address C/ Prime Company Compliance, 505 Little Collins Street, Level 9, Melbourne, VIC, AUS, 3000
Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.